Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Table 2 Modeling on risk of progression on ibrutinib

Variable	PP versus CR/PR			SD versus CR/PR
Variable	RR	95% CI	p value	RR	95% CI	p value
Age at diagnosis	1.02	0.96–1.08	0.61	0.99	0.96–1.03	0.65
Gender
Male	Referent
Female	1.05	0.34–3.22	0.93	1.22	0.54–2.78	0.63
BMI
< 30	Referent
≥ 30	0.95	0.22–4.04	0.94	1.14	0.43–3.01	0.79
ECOG PS at diagnosis
0	Referent
1	0.39	0.10–1.46	0.16	0.66	0.25–1.73	0.40
≥ 2	1.04	0.09–11.61	0.97	1.28	0.19–8.75	0.80
MZL subtype
NMZL	Referent
SMZL	1.32	0.31–5.63	0.71	0.78	0.27–2.19	0.63
EMZL	1.40	0.38–5.20	0.61	0.69	0.26–1.79	0.44
Stage at diagnosis
1–2	Referent
3–4	1.18	0.23–6.06	0.84	0.92	0.31–2.75	0.88
B symptoms at diagnosis
No	Referent
Yes	0.58	0.15–2.30	0.44	0.65	0.24–1.76	0.40
LDH higher than institutional baseline
No	Referent
Yes	1.37	0.35–5.28	0.65	0.84	0.30–2.33	0.73
Monoclonal protein at diagnosis
No	Referent
Yes	3.46	0.64–18.84	0.15	0.41	0.14–1.19	0.10
BM involvement at diagnosis
No	Referent
Yes	0.60	0.16–2.15	0.43	0.85	0.33–2.20	0.74
TP53 mutation/17p deletion
No
Yes	0.76	0.08–7.25	0.81	0.81	0.15–4.48	0.81
Complex cytogenetics
No
Yes	4.63	0.81–26.35	0.08	1.63	0.32–8.21	0.55
Primary refractory disease*
No
Yes	3.77	1.15–12.33	0.03	1.72	0.66–4.47	0.26
Line of ibrutinib therapy
Second line
Third line	0.82	0.23–2.90	0.76	0.65	0.24–1.70	0.38
Fourth line and beyond	1.21	0.26–5.54	0.81	1.76	0.62–5.04	0.29

CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, MZL marginal zone lymphoma, LDH lactate dehydrogenase, BM bone marrow
*Primary refractory disease: defined as progression of disease at the end of induction therapy or within 6 months of treatment completion

ISSN: 1756-8722